SCHEMBL6108406

SCHEMBL6108406

CC(C)(C)OC(=O)N1CCC(C(=O)Nc2ccccc2C(=O)Nc2ccc(Cl)cn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 13/20 0.58
▸ NR3C1 P04150 2/20 0.52
▸ STS P08842 1/20 0.51
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ PTBP1 P26599 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ PTPN2 P17706 1/20 0.48
▸ PTPN1 P18031 1/20 0.48
▸ PTPN6 P29350 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6107829 0.91 F10 (0.61) F10NR3C1STSTP53PTPN2
SCHEMBL5384090 0.91 F10 (0.71) F10NR3C1STS
SCHEMBL6773664 0.90 F10 (0.57) F10NR3C1STSTP53PTPN2
SCHEMBL6106396 0.89 F10 (0.54) F10NR3C1STSLMNATP53
SCHEMBL6108664 0.89 F10 (0.63) F10NR3C1STSTP53
SCHEMBL6107640 0.89 F10 (0.50) F10NR3C1NPC1ALOX15HTT
SCHEMBL6769258 0.88 F10 (0.51) F10NR3C1STSPTPN2PTPN1
SCHEMBL6106348 0.88 F10 (0.51) F10NR3C1STSPTPN2PTPN1
SCHEMBL6109171 0.88 F10 (0.57) F10NPC1ALOX15HTTRAB9A
SCHEMBL6109232 0.88 F10 (0.62) F10NR3C1STSPTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129245-B2 Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots ELI LILLY AND COMPANY (US) 2006-10-31 — — US disclosed
US-20050282862-A1 Aromatic amides BEIGHT DOUGLAS W 2005-12-22 — — US disclosed
EP-1140903-B1 AROMATIC AMIDES LILLY CO ELI (US) 2004-08-04 — — EP disclosed
US-6759414-B2 ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS ELI LILLY AND COMPANY 2004-07-06 — — US disclosed
US-20040029874-A1 Aromatic amides BEIGHT DOUGLAS WADE (US) 2004-02-12 — — US disclosed
US-6635657-B1 Pyridine derivatives; anticoagulants ELI LILLY AND COMPANY 2003-10-21 — — US disclosed
EP-1140903-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029874-A1 Aromatic amides F11, F12, F5 F10 12/4885NR3C1 4435/4885STS 331/4885
US-20050282862-A1 Aromatic amides F11, F12, F5 F10 12/4885NR3C1 4435/4885STS 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback